Investing.com — Shares of SELLAS Life Sciences Group (NASDAQ: SLS) jumped 240% after the company announced positive top-line results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic vaccine for acute myeloid leukemia.
Our AI stock portfolio beats the S&P 500 by 118%. Find out what stocks we’re buying and what opportunities we’re watching next. Exclusive to Yahoo! Financial readers: 55% off for Black Friday, plus an extra 15% at checkout. Subscribe today! »
The REGAL trial met its primary endpoint of overall survival, with GPS demonstrating a 41% reduction in the risk of death compared to the best available treatment. The trial showed a median overall survival of 24.0 months for GPS-treated patients compared to 14.7 months for the control group, with a hazard ratio of 0.59 and a two-sided p-value of 0.035.
The trial evaluated GPS as maintenance monotherapy in patients with acute myeloid leukemia who achieved complete remission at least a second time after second-line or higher salvage therapy and who were ineligible or unable to undergo allogeneic stem cell transplantation.
Stop chasing stocks once they have already rebounded. Find your next investment opportunity with AI stock selection, earnings insights, and market development news. Yahoo! Financial readers get an extra 15% off on top of the 55% off Black Friday price. Join us today! »
GPS was generally well tolerated, with a safety profile consistent with previous clinical experience and no new safety signals were identified. Treatment-related adverse events were mostly mild to moderate, most commonly consisting of local reactions at the injection site.
Analysis of primary endpoint data was performed following the prespecified occurrence of 80 events, in accordance with the trial’s prespecified statistical analysis plan. SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an expedited filing strategy and advance preparations for submitting a Biologics License Application for GPS in the first half of 2027.
A full statistical evaluation of all secondary endpoints and additional prespecified analyzes are underway and will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal.
Original article
SELLAS Life Sciences stock soars 240% following positive cancer trial
European stocks fall on new US chip restrictions; Nvidia expected
Bernstein reduces PepsiCo to underperformance in the face of North American pressure
Gn bussni
